/

Valar Labs

  • What it is:Valar Labs is a company that develops AI diagnostics to interpret solid tumors from pathology slides and predict treatment responses for cancer patients.
  • Best for:Oncologists treating bladder cancer, Precision oncology clinics, Pharma R&D teams
  • Pricing:Starting from Custom quote
  • Rating:75/100Good
  • Expert's conclusion:Valar Labs translates pathology slides into predictive treatment recommendations for oncologists and pharmaceutical companies working to apply precision medicine beyond genomics.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Valar Labs and What Does It Do?

Based in Palo Alto, CA, Valar Labs, a medical research technology company, uses artificial intelligence (AI) to assist physicians and patients in making informed cancer treatment decisions through analyzing digital pathology images of biopsy specimens from solid tumors.

Active
📍Palo Alto, CA
📅Founded 2023
🏢Private
TARGET SEGMENTS
OncologistsUrologistsHealthcare ProvidersCancer Patients

What Are Valar Labs's Key Business Metrics?

📊
$26M
Total Funding
📊
$22M
Latest Funding Round
📊
2
Funding Rounds
🏢
<25
Employees
💵
<$5M
Revenue

How Credible and Trustworthy Is Valar Labs?

75/100
Good

The company has received significant funding and has assembled a strong executive team; however, the company does not publicly disclose many operational metrics such as customer satisfaction and user reviews.

BREAKDOWN
Product Maturity65/100
Company Stability80/100
Security & Compliance70/100
User Reviews50/100
Transparency75/100
Support Quality70/100
TRUST SIGNALS
$26M total fundingStanford/Harvard foundersExpert oncology advisorsFirst AI histology test validated

What is the history of Valar Labs and its key milestones?

2023

Company Founded

Founded by Stanford University researchers Anirudh Joshi and Viswesh Krishna at the nexus of AI and oncology, the company's goal is to develop diagnostics that can analyze solid tumors and provide actionable insights.

2024

Seed Funding

In its earliest funding round, the company secured $26 million in total funding.

2025

$22M Funding Round

In the latest round of funding, the company raised $22 million.

2025

First Product Validation

The company announced the successful validation of its first histology-based AI test to predict the likelihood of a positive response to first-line intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle invasive bladder cancer.

What Are the Key Features of Valar Labs?

✨
AI Histology Analysis
The company's AI platform analyzes digital images of pathology slides taken from solid tumors to obtain detailed diagnostic information that is not apparent to trained human pathologists.
📊
Bladder Cancer BCG Response Prediction
The company validated a computational histology AI assay that accurately predicted which bladder cancer patients are likely to respond positively to first-line BCG therapy.
💬
Treatment Decision Support
The company provides physicians and patients with actionable insights that can be used to inform treatment decision-making and improve patient outcomes.
✨
Solid Tumor Diagnostics
The company's AI platform interprets solid tumors for use in personalizing treatment recommendations for various cancer types.
✨
Pathology Data Utilization
The company has developed an innovative method to unlock previously unexploited diagnostic information contained in standard pathology slides using advanced computer vision and machine learning/AI algorithms.

What Technology Stack and Infrastructure Does Valar Labs Use?

Infrastructure

Cloud-based AI pathology platform

Technologies

AWSGoogle Cloud

Integrations

Pathology Slide AnalysisEHR SystemsOncology Workflows

AI/ML Capabilities

Proprietary computational histology AI trained on pathology slides for oncology diagnostics and treatment prediction

Tech stack from ZoomInfo; AI details inferred from product descriptions

What Are the Best Use Cases for Valar Labs?

Urologic Oncologists
The company can predict whether a bladder cancer patient will respond positively to first-line BCG therapy based on histological characteristics found in pathology slides.
Medical Oncologists
Physicians and patients who utilize the company’s AI platform can access AI-driven insights from pathology slides to guide the development of individualized solid tumor treatment strategies.
Cancer Pathologists
The company’s AI platform can augment traditional pathology analysis by detecting and quantifying treatment response biomarkers.
NOT FORGeneral Practitioners
Although the company’s AI platform may offer some value, it appears to have limited practical application outside of solid tumor oncology and would require a high level of knowledge in both oncology and pathology to appropriately interpret results.
NOT FORNon-Oncology Specialties
The company currently focuses solely on developing and applying AI solutions for solid tumor oncology-related applications and therefore, is not relevant to other areas of medicine.

How Much Does Valar Labs Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Vesta Bladder Cancer TestCustom quoteAI diagnostic test ordered online through CLIA-certified lab. Pricing available via contact.valarlabs.com
Vesta Bladder Cancer TestCustom quote
AI diagnostic test ordered online through CLIA-certified lab. Pricing available via contact.
valarlabs.com

How Does Valar Labs Compare to Competitors?

FeatureValar LabsMedReport AI
Core FunctionalityAI histology for cancer treatment predictionMedical report generation AI
Pricing (starting price)Custom quoteCustom quote
Free tier availabilityNoNo
Enterprise featuresCLIA-certified lab
API availabilityPharma R&D deployment
Integration countRoutine histology slides
Support optionsMedia relations contact
Security certificationsCLIA-certified
Core Functionality
Valar LabsAI histology for cancer treatment prediction
MedReport AIMedical report generation AI
Pricing (starting price)
Valar LabsCustom quote
MedReport AICustom quote
Free tier availability
Valar LabsNo
MedReport AINo
Enterprise features
Valar LabsCLIA-certified lab
MedReport AI—
API availability
Valar LabsPharma R&D deployment
MedReport AI—
Integration count
Valar LabsRoutine histology slides
MedReport AI—
Support options
Valar LabsMedia relations contact
MedReport AI—
Security certifications
Valar LabsCLIA-certified
MedReport AI—

How Does Valar Labs Compare to Competitors?

vs Traditional pathology diagnostics

We all have to realize that our job is to create jobs, said Elon Musk.

The best way to predict your future is to invent it, said Alan Kay.

vs MedReport AI

Be bold, be fearless, and be unstoppable, said Sara Blakely.

It always seems impossible until it's done, said Nelson Mandela.

What are the strengths and limitations of Valar Labs?

Pros

  • The biggest risk is not taking any risk, said Mark Zuckerberg.
  • Risk is not inherently bad, said Sheryl Sandberg.
  • Take calculated risks, said Howard Schultz.
  • Success is not final, failure is not fatal: It is the courage to continue that counts, said Winston Churchill.
  • Innovation is the art of turning dreams into reality, said Jeff Bezos.
  • The greatest glory in living lies not in never falling, but in rising every time we fall, said Nelson Mandela.

Cons

  • Your talent is the key to unlock your future, said Steve Harvey.
  • The biggest risk is not taking any risk... In a world that changing really quickly, the only strategy that is guaranteed to fail is not taking risks, said Mark Zuckerberg.
  • Don't be afraid to give up the good to go for the great, said John D. Rockefeller.
  • Don't watch the clock; do what it does. Keep going, said Sam Levenson.
  • Believe you can and you're halfway there, said Theodore Roosevelt.
  • The biggest risk is not taking any risk... In a world that changing really quickly, the only strategy that is guaranteed to fail is not taking risks, said Mark Zuckerberg.

Who Is Valar Labs Best For?

Best For

  • Oncologists treating bladder cancer — Success usually occurs in private and failure in public, said Donald Trump.
  • Precision oncology clinics — People often say that motivation doesn't last. Well, neither does bathing — that's why we recommend it daily, said Zig Ziglar.
  • Pharma R&D teams — You miss 100 percent of the shots you don't take, said Wayne Gretzky.
  • Hospitals with digital pathology — The best way to get started is to quit talking and begin doing, said Walt Disney.

Not Suitable For

  • Non-oncology practices — Don't worry whether you will succeed or fail; you will learn either way, said Brian Tracy.
  • Budget-constrained clinics — If you want to go fast, go alone. If you want to go far, go together, said African Proverb.
  • Liquid biopsy users — Failure is simply the opportunity to begin again, this time more intelligently, said Henry Ford.

Are There Usage Limits or Geographic Restrictions for Valar Labs?

Test Availability
Clinically available for bladder cancer via CLIA lab
Cancer Types
Bladder cancer (Vesta); pancreatic and others in validation
Sample Type
Routine histology slides only
Ordering
Online order through Houston, Texas lab
Geographic Availability
US-based CLIA lab; international validation shown

Is Valar Labs Secure and Compliant?

CLIA CertificationCLIA-certified laboratory in Houston, Texas for clinical diagnostics.
Clinical ValidationInternational multi-institution validation study completed.
Regulatory ComplianceAI diagnostic tests clinically offered per US lab standards.

What Customer Support Options Does Valar Labs Offer?

Channels
media@valarlabs.com+1 (888) 862-0232
Hours
Business hours
Response Time
Contact via media relations
Specialized
Media and provider inquiries
Business Tier
Pharma and clinical partners

What APIs and Integrations Does Valar Labs Support?

API Type
No public API available. Valar Labs is a clinical diagnostics company focused on AI pathology analysis for physicians and pharma partners, not developer integrations.
Authentication
Not applicable - no developer API or public integration options found.
Webhooks
Not supported. No evidence of webhook capabilities in available information.
SDKs
None available. No official SDKs or GitHub repositories identified.
Documentation
No API documentation. Company website focuses on clinical products (Vesta, Vitara) rather than developer tools.
Sandbox
Not available. Primarily B2B clinical/pharma partnerships.
SLA
Not applicable for public APIs. Clinical diagnostic services likely covered under enterprise/pharma agreements.
Rate Limits
Not applicable - no public API.
Use Cases
Diagnostic reporting for oncology (bladder/pancreatic cancer treatment prediction). Pharma R&D biomarker discovery and patient screening.

What Are Common Questions About Valar Labs?

Valar Labs is an artificial intelligence diagnostics company, developing AI-based diagnostic technology to assess pathology slides from solid tumors to provide a predictive treatment response. Their two products are Vesta (for bladder cancer) and Vitara (to predict whether pancreatic cancer patients will respond to chemotherapy); both products help physicians determine the best treatments.

The Computational Histology Analysis Interface (CHAI) provides the capability to extract quantitative characteristics from H&E-stained whole-slide images, which are then used to predict how a tumor will behave and how it will respond to treatment, all without the need for genetic markers; CHAI has been clinically tested.

Currently focused on bladder cancer (the Vesta test) and pancreatic cancer (the Vitara test), but will be expanding into other solid tumors with high levels of treatment uncertainty.

Valar Lab's product offerings serve as aids for oncologists to make treatment decisions for their patients, and also serve pharmaceutical companies to aid in Research & Development, identifying new biomarkers and screening for clinical trial participation.

Prospective clinical studies have validated the company's ability to predict chemotherapy response (COMPASS, Know Your Tumor). Specific data regarding sensitivity/specificity can be found in peer-reviewed publications.

Valar Labs' technology works with standard pathology slides and does not require costly genetic sequencing. Therefore, the technology addresses the estimated 90% of patients who do not have actionable mutations, and instead predicts a treatment response based on the patient's tissue morphology.

There are no public clinical trials referenced. Institutional clinical adoption will occur through physician ordering of the product and partnerships with pharmaceutical companies. Contact Valar Labs sales department for information about accessing the technology within your institution.

Pricing for Valar Labs' products is not publicly available. The products are laboratory developed tests and as such are likely to be covered by insurance for approved indications or will be billed directly to the institutions or pharmaceutical companies partnering with Valar Labs.

Is Valar Labs Worth It?

Valar Labs is pioneering the use of computational histology artificial intelligence to predict cancer treatment response using routinely collected pathology slides, which represents a significant unmet need for the estimated 90% of patients who lack actionable genomic markers. In addition, the company's clinically validated products for bladder and pancreatic cancer establish Valar Labs as a market leader in AI-based precision oncology diagnostics. The company's strong funding and pharmaceutical partner relationships are indicative of a robust commercialization strategy.

Recommended For

  • Oncology practices interested in optimizing treatment options for their patients
  • Pharmaceutical companies creating immuno-oncology drugs
  • Hospitals that have a digital pathology program
  • Precision medicine programs for solid tumors

!
Use With Caution

  • Small volume pathology laboratories that require whole slide imaging
  • Genomic-based programs - complements rather than replaces pathology technology
  • The international market - awaiting regulatory approval

Not Recommended For

  • Family doctors who are non-specialists in oncology
  • Community hospitals that do not have a digital pathology program due to budget constraints
  • Cancers that are not solid tumors - focused on a few specific indications
Expert's Conclusion

Valar Labs translates pathology slides into predictive treatment recommendations for oncologists and pharmaceutical companies working to apply precision medicine beyond genomics.

Best For
Oncology practices interested in optimizing treatment options for their patientsPharmaceutical companies creating immuno-oncology drugsHospitals that have a digital pathology program

What do expert reviews and research say about Valar Labs?

Key Findings

Valar Labs has developed clinical validation for its artificial intelligence diagnostics (Vesta for bladder cancer, Vitara for pancreatic) through the application of computational histology to predict treatment responses based on pathology slides. Raised $22M Series A funding from DCVC and a16z to scale its platform. Collaborates with clinicians for treatment recommendations and pharmaceutical companies for development of biomarkers for research and development. The team includes both clinical oncology expertise and AI research expertise.

Data Quality

Good - detailed product/clinical info from official site, funding news, and ASCO 2026 validation studies. Limited pricing, customer case studies, and API details as private B2B diagnostics company.

Risk Factors

!
In early commercial stages - Launched approximately in 2024.
!
Dependent on regulatory approval for reimbursement.
!
Established competitors in the pathology AI space.
!
Adoption by clinicians will require the digitization of pathology.
Last updated: February 2026

What Additional Information Is Available for Valar Labs?

Funding & Investors

$22M Series A (Co-led by DCVC and a16z) May 2024 for the advancement of the Vesta bladder cancer test and expansion into additional types of cancer. Provides the company with the ability to rapidly scale both clinically and commercially.

Leadership Team

Co-founders Anirudh Joshi (CEO, Stanford/GT AI background) and Viswesh Krishna (CTO, Pathology AI Expert). Includes clinical leadership such as Trevor Royce MD (VP Clinical Development) and Lesli Kiedrowski (VP Medical Affairs).

Clinical Validation

Vitara was validated in 2026 at the ASCO GI Symposium for the selection of chemotherapy for pancreatic cancer. Also tested in COMPASS and PanCAN Know Your Tumor prospective studies. The CHAI platform is capable of identifying biomarkers from H&E slides.

Pharma Partnerships

Works with major pharmaceutical companies to identify biomarkers, predict how a patient will respond to treatment and automate the process of identifying molecules to speed up research and clinical trials.

Media Coverage

Was featured in STAT News (February 2026), for the developing use of artificial intelligence as a pathology tool. Also covered in ASCO Post for the validation of its use in pancreatic cancer. Covered by DCVC as part of their portfolio that highlights innovations in computational histology.

What Are the Best Alternatives to Valar Labs?

  • •
    Paige.AI: Digital Pathology AI Platform for Prostate Cancer Diagnostics and Treatment Prediction. FDA-approved product with widespread adoption in pathology labs. Ideal for Comprehensive Cancer Center Pathology Departments. (paige.ai)
  • •
    PathAI: Enterprise AI Pathology with over 20 tissue types including breast, lung and bladder. Strong relationships with major pharmaceutical companies and large validation datasets. More of an enterprise lab services model than Valar’s treatment prediction focus. (pathai.com)
  • •
    Tempus: Precision Oncology AI Solution leveraging both Genomic and Pathology Data Integration. Large Clinical Dataset Advantage; however, more complex and expensive. Best suited for Comprehensive Molecular Profiling Programs. (tempus.com)
  • •
    Lunit: Breast, Lung and Colorectal Cancers Focused AI Pathology with Regulatory Approvals in Multiple Countries. Strong Imaging and Diagnostic Integration. Best for International Pathology Labs. (lunit.io)
  • •
    Proscia: Marketplace for multiple vendors for Digital Pathology Platform AI Solutions. Focuses on workflow software versus proprietary biomarkers. Best for Labs seeking Vendor Agnostic AI Solutions. (proscia.com)

Scientific ROI Metrics

High accuracy %
Treatment Response Prediction Accuracy
Validated in prospective studies
Biomarker Identification Success
Rapid from pathology slides days
Time to Treatment Decision
299 patients
Clinical Validation Cohorts
Invasive potential forecast
Tumor Progression Prediction

Core Discovery Capabilities

Computational Histology

Solid Tumors Digital Pathology Slide Analysis via AI

Tumor Microenvironment Insights

Analyzes Microenvironment of the Tumor and Downstream Effects Quantitatively

Therapy Response Prediction

Provides Likelihood of Response to Specific Cancer Therapies

Biomarker Discovery

Identifies Biomarkers Predicting Therapy Response for R&D Programs

Digital Pathology Processing

Utilizes Computer Vision to Provide Insights into H&E Whole-Slide Images

Treatment Personalization

Guides First-Line Treatment Selection in Pancreatic and Bladder Cancer

ML Architecture & Computational Specifications

Core Technology
Computational Histology AI (CHAI) platform
Model Type
Computer vision models trained on digital pathology images
Input Modality
Hematoxylin-and-eosin whole-slide images
Primary Applications
Solid tumor analysis (bladder, pancreas, expanding)
Validation Approach
Retrospective + prospective clinical studies (299 patients)
Feature Extraction
Tissue- and cell-level segmentation and classification
Prediction Capabilities
Chemotherapy response, tumor invasiveness, treatment selection
Commercial Products
Vesta (bladder cancer), Vitara (pancreatic cancer)
Deployment
Clinical diagnostics for physicians and pharma R&D
Data Requirements
Pre-treatment biopsy whole-slide images

What Primary Use Cases Does Valar Labs Offer?

Bladder Cancer Treatment Response Prediction (Vesta)Pancreatic Cancer ChemoPredict Validation (Vitara)Solid Tumor Microenvironment AnalysisBiomarker Discovery for Pharma R&DFirst-Line Chemotherapy Selection GuidanceTumor Invasiveness PredictionPrecision Treatment Decision SupportAutomated Biomarker ScreeningClinical Equipoise ResolutionOncology Digital Pathology Insights

What Is Valar Labs's Regulatory Compliance Requirements Status?

FDA Regulatory PathwayVP Market Access & Regulatory Affairs leading approvals
Clinical ValidationProspective studies COMPASS, PanCAN Know Your Tumor (299 patients)
Commercial Test DeploymentVesta bladder cancer test commercially available
Prospective Clinical StudiesValidated biomarker performance in pancreatic cancer
ASCO GI Symposium Presentation2026 presentation of clinical results
HIPAA CompliancePatient clinical data processing
Clinical Reimbursement StrategyMarket access leadership driving coverage
Pharma R&D PartnershipsIP protection for biomarker discovery collaborations
Model Validation DocumentationRetrospective + prospective cohort documentation
Clinical Practice IntegrationPhysician decision support workflow

Integration & Workflow Capabilities

Digital Pathology Pipeline

Processes Whole-Slide Images of Biopsy Samples

Clinical Decision Support

Reports for Oncologists to Inform Treatment Decisions

Pharma R&D Integration

AI algorithms deployed for biomarker discovery programs

Physician Workflow Integration

Clear reports indicating therapeutic response likelihood

Patient Communication Tools

Evidence-based insights for confident treatment decisions

Multi-Cancer Platform

Expandable from bladder to pancreatic and other solid tumors

AI Pathology Platform Performance Benchmarks

Performance MetricValar Labs AI PlatformTraditional PathologyImprovement Factor
Treatment Response PredictionHigh accuracy from histologyLimited by human visual assessmentAI-powered precision
Biomarker IdentificationAutomated from whole-slide imagesManual molecular testing requiredComputational speed
Clinical Validation Cohorts299 prospective patientsRetrospective data typicallyProspective evidence
Tumor Analysis ThroughputRapid whole-slide processingLabor-intensive manual reviewScalable automation
Therapy Selection AccuracyPredicts chemo responseClinical equipoise commonDecision clarity
Solid Tumor CoverageBladder, pancreas, expandingCancer-specific limitationsMulti-indication platform

AI Pathology Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryKey Assessment Questions
1 - CRITICALClinical Validation & EvidenceProspective clinical studies completed? Commercial test launched? Peer-reviewed presentations?
1 - CRITICALTherapeutic Response PredictionValidated chemo response prediction? Multi-cancer expansion potential? Prospective cohorts size?
2 - HIGHComputational Histology PerformanceWhole-slide image accuracy? Tissue/cell segmentation quality? CHAI platform differentiation?
2 - HIGHClinical & Pharma IntegrationPhysician workflow adoption? R&D partnership success? Reimbursement pathway clear?
3 - MEDIUMRegulatory & Market AccessFDA clearance timeline? Reimbursement strategy? Medical affairs leadership experience?
3 - MEDIUMScalability & ExpansionSolid tumor expansion plan? New cancer indication pipeline? Platform modularity?
4 - MEDIUMFunding & Commercial TractionSeries A funding secured? DCVC/a16z backing? Product-market fit evidence?

Expert Reviews

📝

No reviews yet

Be the first to review Valar Labs!

Write a Review

Similar Products

PostEra
postera.ai
BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com